Description

Composition
Sharpkil Plus 250/62.5 Tablet: Each tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 250
mg and diluted Potassium Clavulanate BP equivalent to Clavulanic Acid 62.5 mg.
Sharpkil Plus 500/125 Tablet: Each tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 500 mg
and diluted Potassium Clavulanate BP equivalent to Clavulanic Acid 125 mg.
Sharpkil Plus powder for suspension: After reconstitution each 5 ml suspension contains Cefuroxime 125
mg as Cefuroxime Axetil USP and Clavulanic Acid 31.25 mg as diluted Potassium Clavulanate BP.
Pharmacology
Cefuroxime is one of the bactericidal second generation cephalosporin antibiotics, which is active against a wide range of Gram-positive and Gram-negative susceptible organisms including many b-lactamase
producing strains. It is indicated for the treatment of infections caused by sensitive bacteria. The presence of clavulanic acid in Sharpkil Plus formulations protects Cefuroxime from degradation by beta-lactamase
enzymes and effectively extends the antibacterial spectrum of Cefuroxime to include many bacteria normally resistant to Cefuroxime and other cephalosporins.
Indications and Uses
Pharyngitis/tonsillitis, acute bacterial otitis media, acute bacterial maxillary sinusitis, lower respiratory tract
infections including pneumoniae, Staphylococcus aureus, acute bacterial exacerbations of chronic bronchitis
and secondary bacterial infections of acute bronchitis, skin and skin-structure Infections, urinary tract
infections, bone and joint infections, gonorrhea, uncomplicated and disseminated gonococcal infections due to
neisseria gonorrhoeae in both males and females, early lyme disease, septicemia & meningitis